Prospective evaluation of sexual health in breast cancer women during the first year of adjuvant hormonal treatment using a cancer patient's dedicated questionnaire: A glaring gap of communication between health professionals and patients

2021 ◽  
Author(s):  
Leticia Aptecar ◽  
Frederic Fiteni ◽  
Marta Jarlier ◽  
Stephanie Delaine ◽  
Violaine Guillerme ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sexual Health ◽  
Health Professionals ◽  
Hormonal Treatment ◽  
First Year ◽  
Prospective Evaluation ◽  
Adjuvant Hormonal Treatment

Survival outcome and treatment tolerability for postmenopausal females with early stage hormone receptor positive breast cancer treated with different adjuvant hormonal lines (TAM vs. AI vs. switching strategy) for 5 years

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Atef Youssef Riyad ◽  
Dalia Abdelghany Elkhodary ◽  
Wesam Reda Farag Elghamry ◽  
Islam Abdelrahman Kamel Mohamed Zaki
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitor ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Hormone Receptor ◽  
Disease Free Survival ◽  
Hormonal Treatment ◽  
Hormone Receptor Positive ◽  
Adjuvant Hormonal Treatment ◽  
Her 2

Abstract Background The standard adjuvant endocrine treatment for postmenopausal female patients with hormone receptor positive early breast cancer was 5 years of tamoxifen, but recurrence and side effects restrict its usefulness. The aromatase inhibitor (anastrozole or exemestane or letrozole) was compared with tamoxifen for 5 years or started after completing 2-3 years of tamoxifen in postmenopausal female patients diagnosed with early breast cancer at "Ain Shams University Hospitals" Objective The aim of the study was to measure survival outcome and treatment tolerability for postmenopausal females with Hormone Receptor Positive early breast cancer who received adjuvant hormonal treatment with tamoxifen [TAM] only for 5 years versus those who received adjuvant hormonal treatment with tamoxifen [TAM] for 2 years switching to aromatase inhibitors [AI] in the sequential 3 years versus those who received adjuvant hormonal treatment with aromatase inhibitors [AI] solely for 5 years. Patients and methods This study included 100 postmenopausal women with early breast cancer who presented at the Clinical Oncology Department, Ain Shams University, in the interval from January 2010 until December 2015. Conclusion Similar disease free survival and overall survival were observed among the three studied groups. Switching tamoxifen to aromatase inhibitors provides better tolerability in terms of endometrial thickness when compared to 5 years of tamoxifen monotherapy. Patients who administer aromatase inhibitor included in the switching strategy experience less osteoporosis and less generalized bone pain compared to upfront aromatase inhibitor to 5 years. There was a significant improvement of disease free survival (DFS) in human epidermal growth factor receptor 2 (HER 2) negative patients receiving any adjuvant hormonal treatment line for five years in comparison to HER 2 positive patients receiving the same adjuvant hormonal treatment for five years.

scholarly journals Effects of ‎tamoxifen on the reproductive system of female breast cancer patients: an ultrasound-based cohort study

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 102
Author(s):  
Ghasak Kais Abd-Alhussain‎ ◽  
Mohammed Qasim Yahya Mal-Allah Alatrakji‎ ◽  
Wieeam Abdulfattah Saleh‎ ◽  
Hayder Adnan Fawzi ◽  
Aqeel‎ Shaker Mahmood‎
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Side Effects ◽  
Endometrial Thickness ◽  
Menopausal Status ◽  
Hormonal Treatment ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Er Positive ◽  
Adjuvant Hormonal Treatment

Background: Tamoxifen (TMX) is regarded as standard treatment for breast cancer (BC) patients‎. In recent years, several studies have reported gynecological side effects and due to TMX's estrogenic effects. Here, we evaluate the side effects of TMX on the ‎endometrium and ovaries of female BC patients. Methods: This was an ultrasound-based cohort study conducted in three oncology centers in Baghdad, Iraq. A total of ‎‎255 female patients were included, 140 premenopausal (PreM) and 115 postmenopausal (PostM), with estrogen receptor (ER)-positive BC using TMX adjuvant hormonal treatment for at least three months after surgery and adjuvant ‎chemo/radiotherapy.‎ Ultrasound (US) on the endometrium and ovaries of the women following ‎BC surgery/chemotherapy (baseline) and at 3, 6, 12, and 24 months following was performed‎. Data collected included age, menopausal status, co-morbid chronic illness and medications, including duration of TMX treatment. Results: Presence of ovarian cyst was significantly higher in the PreM ‎compared to PostM ‎women, while there were no significant differences for other gynecological findings.‎ At ‎baseline, endometrial thickness (ET) was significantly higher in the PreM compared to the PostM women. In both groups, women with increased ET became more frequent from baseline to 3 ‎months, from 3 to 6 ‎months, from 6 to 12 months, and from 12 ‎ to 24 months. At all time periods, ‎women with increased ET was ‎significantly higher in the PostM compared PreM women, resulting ‎in a risk of ET increase by 6 folds (ranging from 3 – ‎‎11 folds) ‎in PostM compared to PreM women. Conclusions: Longer duration of TMX is associated with increased ET. Duration of TMX did not appear to increase the risk of various gynecological outcomes, for example endometrial cancer rate was low. Finally, there was an increase in ET, which appeared to be six-folds higher in PostM compared to PreM women.‎

Adherence to adjuvant hormonal treatment for breast cancer in patients opting for local hospital direct drug distribution in Italy

2013 ◽  
Vol 20 (4) ◽  
pp. 232-235
Author(s):  
Marianna Rivasi ◽  
Raffaella Apollonio ◽  
Laura Cancian ◽  
Teresa Pilade ◽  
Mauro De Rosa
Keyword(s):  
Breast Cancer ◽  
Drug Distribution ◽  
Hormonal Treatment ◽  
Local Hospital ◽  
Adjuvant Hormonal Treatment

Update on adjuvant hormonal treatment of early breast cancer

2011 ◽  
Vol 28 (S6) ◽  
pp. 1-18 ◽  
Author(s):  
Juan Lao Romera ◽  
Teresa de Jesús Puertolas Hernández ◽  
Ignacio Peláez Fernández ◽  
Teresa Sampedro Gimeno ◽  
Roberto Fernández Martínez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Hormonal Treatment ◽  
Adjuvant Hormonal Treatment

Initialization of adjuvant hormonal treatment for breast cancer

2011 ◽  
Vol 28 (S6) ◽  
pp. 66-84 ◽  
Author(s):  
Antonia Martínez Guisado ◽  
Alfonso Sánchez Muñoz ◽  
María de la Cabeza Lomas Garrido ◽  
Manuel Ruíz Borrego ◽  
Juan Bayo Calero ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormonal Treatment ◽  
Adjuvant Hormonal Treatment

Impact of breast cancer diagnosis and treatment on sexual dysfunction.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 125-125 ◽  
Author(s):  
Hadeel Assad ◽  
Gauri Badhwar ◽  
Sameeksha Bhama ◽  
Cynthia Vakhariya ◽  
Judie R. Goodman
Keyword(s):  
Breast Cancer ◽  
Sexual Dysfunction ◽  
Sexual Health ◽  
Cancer Diagnosis ◽  
Breast Cancer Survivors ◽  
Hormonal Treatment ◽  
Breast Cancer Diagnosis ◽  
Well Being ◽  
Diagnosis And Treatment ◽  
Treatment Change

125 Background: Sexual dysfunction is a common and under acknowledged disorder in women with breast cancer. Sexual dysfunction in this scenario may be related to multiple factors: psychological distress due to diagnosis, physical decline due to treatment, change in hormonal milieu and/or poor body image. Methods: We assessed the changes in sexual activity after breast cancer diagnosis and treatment in 45 women using an anonymous questionnaire. Data was analyzed via descriptive statistics and paired sample t-test. Results: The age of women in our study ranged between 33-73 years with an average age of 51.6 years. Most of the subjects (89%) had completed chemotherapy and/or radiation therapy however 52% were still on hormonal treatment. Women who were more sexually active prior to breast cancer diagnosis were more likely to experience sexual dysfunction (p = 0.001). Overall, 45% of the women with breast cancer experienced a decline in their sexual health. A greater decline occurred after breast cancer treatment (chemotherapy and/or hormonal therapy) than after diagnosis (p < 0.05). Fifty percent had a decrease in libido and sexual arousal, 40.5% had difficulty in reaching sexual orgasm, and 29% had dyspareunia. Sexual difficulties were addressed by the treating oncologist in 3 out of the 45 women. Conclusions: The data reveals that sexual dysfunction is prevalent in breast cancer survivors. Its onset in concomitance with the diagnosis of breast cancer reflects the psychosocial impact of such a diagnosis. The further decline in sexual health after treatment emphasizes the important adverse effects of chemotherapy and hormone therapy in terms of vaginal dryness, dysparunia and sexual well-being. Despite its prevalence, sexual dysfunction is not commonly addressed in women with breast cancer. [Table: see text]

scholarly journals A First Sign Not to be Missed: Cutaneous Metastasis from Breast Cancer

2020 ◽  
Author(s):  
Elsa Carina Alves Araújo ◽  
Manuel Barbosa ◽  
Raquel Costa ◽  
Bárbara Sousa ◽  
Vítor Costa
Keyword(s):  
Breast Cancer ◽  
Weight Loss ◽  
Health Professionals ◽  
Metastatic Cancer ◽  
Hormonal Treatment ◽  
Skin Lesions ◽  
Left Breast ◽  
Cutaneous Metastasis ◽  
Lobular Breast Cancer ◽  
New Skin

Cutaneous metastasis has a frequency of 1 to 10% among all metastatic cancer forms and breast cancer accounts for 30% of all cases. We report the case of a 73-year-old woman who presented with 4 skin lesions distributed across the upper trunk and abdomen; these had developed over a period of 12 months. Over the previous 6 months she had also developed anorexia, asthenia and weight loss. Upon investigation, a nodular mass was found in the left breast. Skin and breast mass biopsy were performed. Histology confirmed the diagnosis: infiltrating lobular breast cancer with cutaneous metastasis. The patient underwent hormonal treatment, mastectomy and radiotherapy. In rare cases, cutaneous metastasis appears as the first clinical manifestation of breast cancer. It is therefore crucial for patients and health professionals alike to be aware of new skin lesions. Cutaneous metastasis is a diagnostic sign of cancer that, it must be emphasised, is not restricted exclusively to later forms of the disease.

Sign in / Sign up

Export Citation Format

Share Document